CD₄⁺ T Cell Count in Patients Concomitantly Infected with HIV and Hepatitis B Virus in Sokoto State, Nigeria

M.N. Alo^1, , H.M. Alhassan², A.Y. Saidu², U.I. Ugah³ and F. A. Umar²

¹Department of Biological Science, Federal University, Ndufu-Alike, Ebonyi State, Nigeria

²Department of Immunology, Usmanu Danfodiyo University, Sokoto, Sokoto State, Nigeria

³Department of Medical Laboratory Science, Ebonyi State University, Abakaliki, Ebonyi State, Nigeria

Cite this paper:
M.N. Alo, H.M. Alhassan, A.Y. Saidu, U.I. Ugah and F. A. Umar. CD₄⁺ T Cell Count in Patients Concomitantly Infected with HIV and Hepatitis B Virus in Sokoto State, Nigeria. American Journal of Epidemiology and Infectious Disease. 2013; 1(3):24-26. doi: 10.12691/ajeid-1-3-2

Abstract

Concomitant infection of HIV and HBV is a single most important factor that predispose to poor clinical outcome among patients infected with HIV. This study was aimed at evaluating the CD₄⁺ T cell profile as a marker of immune response and stability in patients infected with HIV and HBV. Five hundred and seventy two HIV infected persons were screened for concomitant infection with HBV using HBV screening kit (Sketec, USA). The CD₄⁺ T cell count were also determined using cyflow cytometer (Patec, Germany) out of these number, 88 persons were positive for HBV representing 15.4%. The mean CD₄⁺ T cell count was 112.3cell/μL, which was significantly lower than the mean CD₄⁺ T cell count of 312.3cells/μL among those infected with only HIV. This indicates that HBV infection could be associated with rapid decline in CD₄⁺ T cell count in HIV infected persons.

Keywords:
HIV HBV CD₄⁺ T cell

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Sepkowitz K.A. AIDS- the first 20 years. New England Journal of Medicine, 2001, 344(23), 1764-1772.
[2]	Del, R., J. Cand and Curran, W Epidemiology and prevention of acquired immunodeficiency syndrome and Human immunodeficiency virus infection. In Principles and Practice of Infectious Diseases. 7th ed. Eds., Mandell G.L., Douglas, R., D. and Bennett J., E. Churchill Livinstone Elsevier. Philadelphia, 2010, Volume1 pp: 1635-1661.
[3]	Holmes C.B., Losina E., Walensky, R.P., Yazdanpanah Y., Freedberg K.A. Review of Human Immunodeficiency Virus Type-1 Related opportunistic infections in sub-saharan Africa. Journal of Clinical Infectious Diseases, 2003, 36(5), 656-662.
[4]	Alter, M. Epidemiology of viral hepatitis and HIV co-infection. Journal of Hepatology, 2006, 44(1), 6-9.
[5]	Chun H.M., Roediger M.P., Huppler K.H., Thio C.L., Agan B.K., Bradley W.P., Peel S.A., Jagodzinski L.L., Weintrob A.C., Ganesan, A., Crum-Cianflone N.F., Maguire J.D., Landrum M.L. Hepatitis B virus co-infection Negatively impacts on HIV outcomes in seroconverters. Journal of Infectious Diseases, online edition, 2011.
[6]	Center for Disease Control and Prevention (CDC). (2011). Updated U.S public health service guidelines for the management of occupational exposure to HBV, HCV and HIV and recommendation for post exposure prophylaxis. CDC MMWR, 2011, 50(RR-11):1-42.
[7]	WHO. Hepatitis B factsheet. World Health Organisation, Geneva, Switzerland, 2012, Available from http://www.who.int/mediacentre/factsheet/fs204/en/ retrieved 27/02/2013.
[8]	Burnett R.J., Francois G., Kew M.C., Leroux-Roels, G., Mehause, A., Hoosen, A. A and Mphahlele, M. J. Hepatitis B virus and Human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver International, 2005, 25, 201-213.
[9]	Bodsworth N.J., Cooper D.A., Donovan B. The influence of human immunodeficiency virus type-1 infection on the development of the hepatitis B virus carrier state. Journal of Infectious Diseases, 1991, 163, 1138-1139.
[10]	Vento S. Di Parri G., Garofano T., Concia E., Basseti D. Reactivation of Hepatitis B in AIDS. Lancet, 1989, 2, 108-109.
[11]	Rodriguez-Mendez M.L., Gonzalez-Quintela A. and Aguilera A. Prevalence, patterns and course of past hepatitis B virus infection in intravenous drug users in HIV-1 infection. American Journal of Gastroenterology, 2000, 95(5), 1316-1322.
[12]	Scharschmidt B.F., Held M.J., Hollander H.H. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Annals of Internal Medicine, 1992, 117(10), 837-838.
[13]	Piroth L., Sene D., and Pol S. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV infected patients. AIDS, 2007, 21(10), 13323-1331.
[14]	Uneke C.J., Ogbu P.U.I., Anyanwu G.I., Njoku M.O and Idoko J.H. Prevalence of Hepatitis B surface antigen among blood donors and HIV infected patients in Jos, Nigeria. Memorias do Instituto Oswaldo cruz Cruz Rio de Janerio, 2005, 100(1), 13-16.
[15]	Eaton D.K., Kann L., KinchenS., Shanklin S., Ross J., Hawkins J., Harris W.A., Lowry R., McManus T., Chyen D., Lim C., Brener N.D., Wechsler, H. Youth risk behavior surveillance- United States, 2007. MMWR Surveillance Summaries, 2008, 57(4), 1-131.
[16]	Mayaphi S.H., Rossow T.M., Masemola D.P., Olorunju S.A.S., Mphahlele M.J. HBV/HIV co-infection: the dynamics of HBV in South African patients with AIDS. South African Medical Journal, 2012, 102(3), 157-162.
[17]	Taura D.W., Oyeyi T.T. and Hafsat M.N. Prevalence of Hepatitis B surface antigen (HBsAg) among HIV positive patients attending Aminu Kano Teaching Hospital, Kano, Nigeria. International Journal of Biomedical and Health Sciences, 2008, 4(1), 33-39.